Here's the London Telegraph
===========================
The Oxford vaccine "provides minimal protection" against mild disease caused by the variant of Covid-19 first discovered in South Africa, according to early data from a small trial.
The study, from South Africa's University of the Witwatersrand and Oxford University, analysed the E484K mutation in some 2,000 people, most of whom were young and healthy.
The team found that the vaccine had "substantially reduced" efficacy against the South African variant compared to the original strain of Sars-Cov-2.
"This study confirms that the pandemic coronavirus will find ways to continue to spread in vaccinated populations, as expected," said Andrew Pollard, chief investigator on the Oxford vaccine trial.
"But, taken with the promising results from other studies in South Africa using a similar viral vector, vaccines may continue to ease the toll on health care systems by preventing severe disease," he added.
The study did not assess protection against moderate-severe disease, hospitalisation or death was not assessed as the target population were at such low risk. But Sarah Gilbert, professor of vaccinology at the University of Oxford, told the BBC she was confident the vaccine would prevent severe illness.
Professor Robin Shattock, who is leading Covid-19 vaccine research at Imperial College London, also urged caution.
"I think everybody should remember that having a vaccine is going to prevent you ending up in hospital with these current strains," he said.
The study comes after research released on Friday indicated that the Oxford/-straZeneca jab is effective at fighting the new UK coronavirus variant.
www.wsj.com
